Artificial intelligence is making significant inroads in the pharmaceutical and biopharmaceutical industries, especially in research and development. By 2032, the worldwide market for AI in drug discovery is expected to reach $13 billion in revenues.
Compounds with defined multi-target activity are candidates for the treatment of multi-factorial diseases. The introduction of transformer-based chemical language model variants allows for the generative design of dual-target compounds.
Collection
[
|
...
]